Pfizer Inc. Files 8-K on Financials

TL;DR

Pfizer dropped its 8-K on Feb 4th - check the financials!

AI Summary

On February 4, 2025, Pfizer Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and exhibits, with the company's principal executive offices located at 66 Hudson Boulevard East, New York, NY 10001-2192. Pfizer Inc. is incorporated in Delaware and operates within the Pharmaceutical Preparations industry.

Why It Matters

This filing provides investors with updated financial information and operational results for Pfizer Inc., crucial for assessing the company's current performance and future outlook.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any unusual risks or events.

Key Players & Entities

• Pfizer Inc. (company) — Registrant
• February 4, 2025 (date) — Date of Report
• 66 Hudson Boulevard East (address) — Principal executive offices
• New York, New York (location) — City and State of principal executive offices
• 10001-2192 (zip_code) — Zip code of principal executive offices
• Delaware (location) — State of incorporation
• 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations

FAQ

Key Financial Figures

• $0.05 — ange on which registered Common Stock, $0.05 par value PFE New York Stock Exchange

Filing Documents

• pfe-20250204.htm (8-K) — 34KB
• pfe-12312024xex99.htm (EX-99) — 939KB
• pfizerlogoa.jpg (GRAPHIC) — 38KB
• 0000078003-25-000017.txt ( ) — 1250KB
• pfe-20250204.xsd (EX-101.SCH) — 3KB
• pfe-20250204_def.xml (EX-101.DEF) — 15KB
• pfe-20250204_lab.xml (EX-101.LAB) — 27KB
• pfe-20250204_pre.xml (EX-101.PRE) — 16KB
• pfe-20250204_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On February 4, 2025, Pfizer Inc. ("Pfizer") issued a press release announcing its financial results for fourth-quarter and full-year 2024. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein. The information furnished pursuant to this "Item 2.02 - Results of Operations and Financial Condition", including Exhibit 99, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Exhibit Description Exhibit 99 Press Release of Pfizer Inc. dated February 4, 2025 , reporting Pfizer's financial results for fourth-quarter and full-year 2024. 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. EXHIBIT INDEX Exhibit No. Description 99 Press Release of Pfizer Inc. dated February 4, 2025, reporting Pfizer's financial results for fourth-quarter and full-year 2024. 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PFIZER INC. By: /s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel Dated: February 4, 2025

View Full Filing

View this 8-K filing on SEC EDGAR